Fig. 3.

Validation of TIES model in 10,469 patient tumor samples across 31 tumor types. (A) Loading of principal component analysis (PCA) of the CIBERSORT-derived immune cell infiltrate composition across 10,469 tumors stratified as antitumor (E; effector) or pro-tumor (S; suppressor). Immune type nomenclature is listed in Supplementary Table 2. (B) The cellular composition (normalized immune cell infiltrate counts and malignant cell burden estimated by CIBERSORT and ESTIMATE, respectively) for each of the 10,469 tumors was derived and plotted onto the TIES map; all tumors localized in regions with a TIES leading to tumor immune evasion.